Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2779-2785

  Salvesen, Helga B ^a,b,c   Iversen, Ole Erik ^b   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTRADIOL RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; ENDOMETRIAL NEOPLASMS; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; S PHASE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031724315     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Rose, P. G. Endometrial carcinoma. N. Engl. J. Med., 335: 640-649, 1996.
2. Abeler, V. M., and Kjørstad, K. E. Endometrial adenocarcinoma in Norway, a study of a total population. Cancer (Phila.), 67: 3093-3103, 1991.
3. Homsley, H., and Zaino, R. Endometrial cancer: prognostic factors. Semin. Oncol., 21: 71-78, 1994.
4. Zaino, R., Kurman, R. J., Diana, K. L., and Morrow, C. P. Pathologic models to predict outcome for women with endometrial carcinoma. Cancer (Phila.), 77: 1115-1121, 1996.
5. Salvesen, H. B., Akslen, L. A., Iversen, T., and Iversen, O. E. Recurrence of endometrial carcinoma and the value of routine follow up. Br. J. Obstet. Gynaecol., 104: 1302-1307, 1997.
6. Salvesen, H. B., Akslen, L. A., Albrektsen, G., and Iversen, O. E. Poorer survival of nulliparous women with endometrial carcinoma. Cancer (Phila.), 82: 1328-1333, 1998.
7. Salvesen, H. B., Iversen, O. E., and Akslen, L. A. Independent prognostic importance of microvessel density in endometrial carcinoma. Br. J. Cancer, 77: 1140-1144, 1998.
8. Cohen, C. Image cytometric analysis in pathology. Hum. Pathol., 27: 482-493, 1996.
9. Iversen, O. E. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am. J. Obstet. Gynecol., 155: 770-776, 1986.
10. Susini, T., Rapi, S., Savino, L., Boddi, V., Berti, P., and Massi, G. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am. J. Obstet. Gynecol., 170: 527-534, 1994.
11. Nordström, B., Strang, P., Lindgren, A., Bergström, R., and Tribukait, B. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res., 16: 899-904, 1996.
12. Strang, P., Nordström, B., Nilsson, S., Bergström, R., and Tribukait, B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur. J. Cancer, 32A: 598-602, 1996.
13. Rotman, M., Aziz, H., Halpern, J., Schwartz, D., Sohn, C., and Choi, K. Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer (Phila.), 71: 1471-1479, 1993.
14. Hall, P. A., and Woods, A. L. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet., 23: 505-522, 1990.
15. Bowen, I. D., Bowen, S. M., and Jones, A. Mitosis and Apoptosis. London: Chapman and Hall, 1998.
16. McCormick, D., Chong, H., Hobbs, C., Datta, C., and Hall, P. A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology, 22: 355-360, 1993.
17. Gerdes, J., Li, L., Schlüter, C., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., and Flad, H. D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol., 138: 867-873, 1991.
18. McCormick, D., and Hall, P. A. The complexities of proliferating cell nuclear antigen. Histopathology, 21: 591-594, 1992.
19. Baisch, H., Gohde, W., and Linden, W. Analysis of PCP data to determine the fraction of cells in various phases of the cell cycle. Rad. Environm. Biophys., 12: 31-37, 1975.
20. Weidner, N., Moore, D. H., and Vartanian, R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody (see comments). Hum. Pathol., 25: 337-342, 1994.
21. Frierson, H. F., Jr. The need for improvement in flow cytometric analysis of ploidy and S-phase fraction (editorial). Am. J. Clin. Pathol., 95:439-441, 1991.
22. Nordström, B., Strang, P., Bergström, R., Nilsson, S., and Tribukait, B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer (Phila.), 78: 1942-1951, 1996.
23. Scott, R. J., Hall, P. A., Haldane, J. S., van Noorden, S., Price, Y., Lane, D. P., and Wright, N. A. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction (see comments). J. Pathol., 165: 173-178, 1991.
24. Cattoretti, G., Becker, M. H., Key, G., Duchrow, M., Schlüter, C., Galle, J., and Gerdes, J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168: 357-363, 1992.
25. Mikuta, J. J. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer (Phila.), 71: 1460-1463, 1993.
26. Scully, R. E., Bonfiglio, T. A., Kurman, R. J., Silverberg, S. G., and Wilkinson, E. J. Histological typing of female genital tract tumours. International histological classification of tumours. Berlin Heidelberg: WHO, Springer-Verlag, 1994.
27. Iversen, O. E., Utaaker, E., and Skaarland, E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet. Gynecol. Scand., 67: 531-537, 1988.
28. Utaaker, E., Iversen, O. E., and Skaarland, E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol. Oncol., 28: 89-100, 1987.
29. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc., 34: 187-220, 1972.
30. Norusis, M. J. SPSS advanced statistics 6.1. Chicago: SPSS Inc., 1994.
31. Hendrickson, M., Ross, J., Eifel, P. J., Cox, R. S., Martinez, A., and Kempson, R. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Gynecol. Oncol., 13: 373-392, 1982.
32. Mittal, K. R., Schwartz, P. E., and Barwick, K. W. Architectural (FTGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high risk and low risk groups. Cancer (Phila.), 61: 538-545, 1988.
33. Creasman, W. T. Prognostic significance of hormone receptors in endometrial cancer. Cancer (Phila.), 71: 1467-1470, 1993.
34. Nyholm, H. C., Christensen, I. J., and Nielsen, A. L. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol. Oncol., 59: 347-351, 1995.
35. Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., and Berchuck, A. Multivariable analysis of DNA ploidy, p53, and HER-2/ neu as prognostic factors in endometrial carcinoma. Cancer (Phila.), 73: 2380-2385, 1994.
36. Geisler, J. P., Wiemann, M. C., Zhou, Z., Miller, G. A., and Geisler, H. E. P53 as a prognostic indicator in endometrial cancer. Gynecol. Oncol., 61: 245-248, 1996.
37. Podratz, K. C., Wilson, T. O., Gaffey, T. A., Cha, S. S., and Katzmann, J. A. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am. J. Obstet. Gynecol., 168: 1206-1215, 1993.
38. Kaleli, S., Kosebay, D., Bese, T., Demirkiran, F., Oz, U. A., Arvas, M., Aydinli, K., and Erkun, E. A strong prognostic variable in endometrial carcinoma: flow cytometric S-phase traction. Cancer (Phila.), 79: 944-951, 1997.
39. Wagenius, G., Bergström, R., Strang, P., Gerdes, U., Rogo, K., Tribukait, B., and Stendahl, U. Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II. Anticancer Res., 12: 725-732, 1992.
40. Thornton, J. G., Ali, S., O'Donovan, P., Griffin, N., Wells, M., and MacDonald, R. R. Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer. Br. J. Obstet. Gynaecol., 100: 253-261, 1993.
41. Pfisterer, J., Kommoss, F., Sauerbrei, W., Rendl, I., Kiechle, M., Kleine, W., and Pfleiderer, A. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol. Oncol., 58: 149-156, 1994.
42. Sorbe, B., Risberg, B., and Thornthwaite, J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int. J. Gynecol. Cancer, 4: 94-100, 1994.
43. Jacobsen, M., Jakobsen, A., Nedergaard, L., Andersen, J. E., and Nielsen, K. Endometrial carcinomas-flow cytometric DNA content and S-phase values. Pathol. Res. Pract., 193: 283-290, 1997.
44. Gassel, A. M., Backe, J., Krebs, S., Schon, S., Caffier, H., and Muller-Hermelink, H. K. Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J. Clin. Pathol., 51: 25-29, 1998.
45. Geisler, J. P., Wiemann, M. C., Zhou, Z., Miller, G. A., and Geisler, H. E. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol. Oncol., 61: 373-377, 1996.
46. Nielsen, A. L., and Nyholm, H. C. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometroid type: comparison of tumours from patients with and without previous oestrogen therapy. J. Pathol., 171: 199-205, 1993.